[1]徐 莹,薛国辉,华 琳.系统性红斑狼疮患者中TAFI、PAI-1及t-PA水平变化及其与疾病活动度的关系[J].医学信息,2020,33(20):54-56.[doi:10.3969/j.issn.1006-1959.2020.20.015]
　XU Ying,XUE Guo-hui,HUA Lin.Changes of TAFI,PAI-1 and t-PA Levels in Patients with Systemic Lupus Erythematosus and Their Relationship with Disease Activity[J].Medical Information,2020,33(20):54-56.[doi:10.3969/j.issn.1006-1959.2020.20.015]
点击复制

系统性红斑狼疮患者中TAFI、PAI-1及t-PA水平变化及其与疾病活动度的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年20期
页码:
54-56
栏目:
论著
出版日期:
2020-10-15

文章信息/Info

Title:
Changes of TAFI,PAI-1 and t-PA Levels in Patients with Systemic Lupus Erythematosus and Their Relationship with Disease Activity
文章编号:
1006-1959（2020）20-0054-03
作者:
徐 莹; 薛国辉; 华 琳
（九江市第一人民医院检验科，江西 九江 332000）
Author(s):
XU Ying; XUE Guo-hui; HUA Lin
(Department of Laboratory Medicine,the First People’s Hospital of Jiujiang City,Jiujiang 332000,Jiangxi,China)
关键词:
血浆凝血酶激活的纤溶抑制物; 纤溶酶原激活物抑制剂; 组织型纤溶酶原激活物; 系统性红斑狼疮
Keywords:
Plasma thrombin activated fibrinolytic inhibitor; Plasminogen activator inhibitor; Tissue plasminogen activator; Systemic lupus erythematosus
分类号:
R593.241
DOI:
10.3969/j.issn.1006-1959.2020.20.015
文献标志码:
A
摘要:
目的 探讨系统性红斑狼疮（SLE）患者中血浆凝血酶激活的纤溶抑制物（TAFI）、纤溶酶原激活物抑制剂（PAI-1）及组织型纤溶酶原激活物（t-PA）水平变化，及其与临床疾病活动度的关系。方法 选取2018年1月~2020年4月我院就诊的SLE患者，其中单纯性SLE患者78例作为单纯性SLE组，狼疮性肾炎患者75例作为狼疮性肾炎组，另选取同期我院50名健康体检者作为对照组，比较三组凝血指标、TAFI、PAI-1及t-PA水平及其与临床疾病活动度的关系。结果 单纯性SLE组和狼疮性肾炎组PT、APTT低于对照组，FDP和D-二聚体高于对照组，差异有统计学意义（P＜0.05）；且狼疮性肾炎组PT、APTT低于单纯性SLE组，FDP和D-二聚体高于单纯性SLE组，差异有统计学意义（P＜0.05）；三组TT、FIB和INR比较，差异无统计学意义（P＞0.05）。单纯性SLE组和狼疮性肾炎组血浆中TAFI、PAI-1浓度高于对照组，t-PA浓度低于对照组，差异有统计学意义（P＜0.05）；且狼疮性肾炎组血浆中TAFI、PAI-1浓度高于单纯性SLE组，t-PA浓度低于单纯性SLE组，差异有统计学意义（P＜0.05）。Spearman相关性分析显示，TAFI和PAI-1的浓度与SLE患者的疾病活动评分SLEDAI均呈正相关（r=0.658、0.681，P＜0.05），而t-PA的浓度与SLE患者的疾病活动度评分SLEDAI间无相关性（P＞0.05）。结论 TAFI、PAI-1、t-PA的浓度与SLE患者的高凝状态具有相关性，其可提示SLE患者疾病严重程度。
Abstract:
Objective To investigate plasma thrombin-activated fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor (PAI-1) and tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus (SLE)level changes and their relationship with clinical disease activity. Methods Selected SLE patients from January 2018 to April 2020 in our hospital, of which 78 patients with simple SLE were treated as the simple SLE group, 75 patients with lupus nephritis were treated as the lupus nephritis group, and 50 patients in our hospital during the same period were selected healthy subjects served as the control group to compare the three groups of coagulation indexes, TAFI, PAI-1 and t-PA levels and their relationship with clinical disease activity.Results The PT and APTT of the simple SLE group and the lupus nephritis group were lower than those of the control group, and the FDP and D-dimer were higher than those of the control group,the difference was statistically significant (P＜0.05); In addition, PT and APTT in the lupus nephritis group were lower than those in the simple SLE group, and FDP and D-dimer were higher than those in the simple SLE group,the difference was statistically significant (P<0.05); There was no significant difference in TT, FIB and INR among the three groups (P>0.05). The concentrations of TAFI and PAI-1 in the plasma of the simple SLE group and the lupus nephritis group were higher than those of the control group, and the t-PA concentration was lower than the control group, the difference was statistically significant (P＜0.05); and the plasma TAFI of the lupus nephritis group the concentration of PAI-1 was higher than that of the simple SLE group, and the concentration of t-PA was lower than that of the simple SLE group, the difference was statistically significant (P<0.05). Spearman correlation analysis showed that the concentrations of TAFI and PAI-1 were positively correlated with the disease activity score SLEDAI of SLE patients(r=0.658, 0.681,P<0.05), and there was no correlation between the concentration of t-PA and the disease activity score SLEDAI of SLE patients (P>0.05).Conclusion The concentrations of TAFI, PAI-1, and t-PA are correlated with the hypercoagulable state of SLE patients, which could indicate the severity of the disease in SLE patients.

参考文献/References:

[1]Mohan C,Putterman C.Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis[J].Nat Rev Nephrol,2015,11(6):329. [2]Matsuura I,Lourenco E,Grossman J,et al.Elevated Level of Plasma Coagulation Factor XIII Correlates To Atherosclerosis In Lupus Patients[J].Clin Exp Rheumatol,2015,33(3):S44. [3]李春,穆荣,任立敏,等.D-二聚体水平在系统性红斑狼疮的临床意义[J].中华内科杂志,2010,49(12):1039-1042. [4]Afeltra A,Vadacca M,Conti L,et al.Thrombosis in systemic lupus erythematosus:congenital and acquired risk factors[J].Arthritis Rheum,2005,53(3):452-459. [5]林小军,蔡小燕.系统性红斑狼疮您者肾损害与血清脂蛋白(a）水平相关性分析[J].实验医学杂志,2006,22(7):773-774. [6]Al-Homood IA.Thrombosis in systemic lupus erythematosus:a review article[J].ISRN Rheumatol,2012(2012):428269. [7]谢军.凝血与纤溶系统水平对产妇弥漫性血管内凝血的早期诊断分析[J].中国卫生检验杂志,2015(15):2528-2529. [8]王振义.血栓与止血基础理论与临床(第二版)[M].上海科学技术出版社,1996. [9]Bonaventura A,Montecucco F,Dallegri F.Update on the effects of treatment with recombinant tissue-type plasminogen activator(rt-PA)in acute ischemic stroke[J].Expert Opin Biol Ther,2016,16(11):1323. [10]Kulwas A,Lisewska B,Jundzi W,et al.Tissue plasminogen activator(t-PA)and plasminogen activator inhibitor type 1(PAI-1)in diabetic foot syndrome[J].Adv Med Sci,2017,62(1):87-91.

更新日期/Last Update: 1900-01-01